Clinical Trials
48 trialsKANDLELIT-001
Merck Sharp & Dohme LLC
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors
Genmab
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Akeso
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)
EMD Serono
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
BeiGene
A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies
Providence Health & Services
A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors
UCB Pharma
A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Study to Assess the Effects of GS-3583 in Participants With Advanced Solid Tumors
Gilead Sciences
AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer
AstraZeneca
Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
University of Nebraska
AToM
AstraZeneca
PD-1 Inhibitor Combined With Bevacizumab and FOLFIRI Regimen in the Second-line Treatment of Advanced Colorectal Cancer
Tianjin Medical University Cancer Institute and Hospital
A Study of the Safety and Efficacy of Atezolizumab Administered in Combination With Bevacizumab and/or Other Treatments in Participants With Solid Tumors
Hoffmann-La Roche
ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin
National Cancer Centre, Singapore
Efficacy and Safety of JMT101 in Patients With Advanced Solid Tumor
Shanghai JMT-Bio Inc.
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Lumos Pharma
A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI
Eli Lilly and Company
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
Dana-Farber Cancer Institute
Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine
ASLAN Pharmaceuticals
A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors
SuZhou Stainwei Biotech Inc.
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment
UNC Lineberger Comprehensive Cancer Center
Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach
SCRI Development Innovations, LLC
A Study of PEP02 in Combination With 5-fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Tumors
PharmaEngine
Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
National Institutes of Health Clinical Center (CC)
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
Valerio Therapeutics
Combination Chemotherapy in Treating Patients Who Have Advanced Solid Tumors
National Cancer Institute (NCI)
UCN-01, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Alvocidib, Oxaliplatin, Fluorouracil, and Leucovorin Calcium in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Fluorouracil Plus UCN-01 in Treating Patients With Advanced or Refractory Solid Tumors
Memorial Sloan Kettering Cancer Center
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Northwestern University
Combination Chemotherapy In Treating Patients With Metastatic or Unresectable Solid Tumors
Mayo Clinic
A Study to Assess Safety, Tolerability and PK of AZD2171 and Chemotherapy on Patients With Solid Tumors
AstraZeneca
Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute